學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Alexion: Digital Co-Innovation Accelerating the Application of Analytics
內容大綱
Alexion Pharmaceutical Inc. (Alexion), founded in 1992, was a biotechnology company that focused on therapeutics for rare diseases. As the company grew, it sought to scale operations to serve a growing number of patients and their families worldwide. The search began for an innovative, forward-thinking, strategic information technology leader to spearhead the effort. In 2015, George Llado was hired as senior vice-president and chief information officer. Llado realized that big data and analytics could play a unique transformational role in identifying customers to accelerate sales growth and realize the mission to save lives. He wondered if analytics enabled through cloud computing, a new kind of data platform, and betting on technology start-ups could accelerate patient identification. When he joined Alexion, Llado faced a unique set of related challenges, including (a) applying analytics in a highly regulated industry, (b) rapidly creating a new type of integrated data platform, (c) managing dysfunctional vendor relationships, and (d) balancing the role of data and analytics in relation to the traditional sales force approach in pharmaceutical firms.